Pharmaceutical Corruption Media Articles

Excerpts of Key Pharmaceutical Corruption Media Articles in Major Media

Below are key excerpts of revealing news articles on pharmaceutical industry corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

Overdoses are now the leading cause of death of Americans under the age of 50. According to preliminary data compiled by The New York Times, deaths last year likely topped 59,000 - 19 percent more than the year before. In Ohio, they were up even more. On May 26, Cleveland Police Sgt. Timothy Maffo-Judd's body camera was running as he approached a man slumped in his car. It turned out that the man was minutes from a fatal drug overdose. Three applications of Narcan - the anti-overdose drug - and the victim finally started coming around. Maffo-Judd says it's become a grim routine, and he's even encountered the same person twice. "That's pretty common," he says. In Ohio, at least 4,100 people died from unintentional drug overdoses last year - a 36 percent increase from 2015, when the state led the nation in overdose deaths. Kentucky, West Virginia and New Hampshire have also experienced shocking increases, along with the East Coast. Most of it is tied to heroin or prescription painkillers, often laced with a powerful synthetic opioid known as fentanyl. In Ohio alone, nearly four billion opioid pills were prescribed across Ohio between 2011 and 2015. Ohio is now suing five big drug companies that manufacture prescription painkillers, charging that they knowingly minimize the risks of addiction. As Attorney General Mike Dewine put it: "They knew they were wrong but they did it anyway and they continue to do it."

Note: This excellent article has lots more on the intense level of corruption found in this opioid crisis. For more, see concise summaries of deeply revealing news articles on corruption in government and in the pharmaceutical industry.

The entire pharmaceutical industry is floated by a protectionist racket. Drugs that are in fact very cheap to make are kept artificially expensive – we have drugs that cost $1,000 a pill here in America that sell for $4 in India, for instance. The means of keeping prices high vary, but include lengthy patents to push production of generics into the future, the barring of foreign competition, and the prohibition of negotiations to lower prices for bulk purchases by both the federal and state governments. Without government intervention, the pharmaceutical industry would be profitable, but it wouldn't be the massive cash factory it is now. In 2015, for instance, the 20 largest drug companies made a collective $124 billion in profits. All the industry needs to protect those sums is the continued cooperation of Congress. So naturally it spends money ... to make sure they always have just enough dependable people in office to block change. Which brings us ... to drug importation. Trump announced early in the race that he was in favor of bringing in cheaper drugs from Canada and made it a big stump theme. The Democrats, meanwhile, put allowing importation of drugs from countries like Canada in their platform last summer. The seeming synergy of the two candidates' positions led to the hope that something might actually be done about the problem, no matter who won. No such luck. Trump's support for drug importation basically went up in smoke from the moment he started filling out his executive appointees.

Note: For more along these lines, see concise summaries of deeply revealing news articles about corruption in government and throughout Big Pharma.

The Food and Drug Administration is under pressure from the Trump administration to approve drugs faster, but researchers at the Yale School of Medicine found that nearly a third of those approved from 2001 through 2010 had major safety issues years after the medications were made widely available to patients. Seventy-one of the 222 drugs approved in the first decade of the millennium were withdrawn, required a "black box" warning on side effects or warranted a safety announcement about new risks, Dr. Joseph Ross ... and colleagues reported in JAMA. The Yale researchers' previous studies concluded that the FDA approves drugs faster than its counterpart agency in Europe does and that the majority of pivotal trials in drug approvals involved fewer than 1,000 patients and lasted six months or less. It took a median of 4.2 years after the drugs were approved for these safety concerns to come to light, the study found, and issues were more common among psychiatric drugs, biologic drugs, drugs that were granted "accelerated approval" and drugs that were approved near the regulatory deadline for approval. "All too often, patients and clinicians mistakenly view FDA approval as [an] indication that a product is fully safe and effective," [Dr. Caleb Alexander] says. "Nothing could be further from the truth. We learn tremendous amounts about a product only once it's on the market and only after use among a broad population."

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and health from reliable major media sources.

Public money and public universities boost Big Pharma’s profits, so shouldn’t the public be able to afford the drugs? Almost 1 in 2 people used a prescription drug in the past month, and more than 1 in 5 used three or more. As the population ages and deals with more chronic diseases like diabetes, heart disease and depression, the percentage of people needing prescription medicines is growing. But what really sets us apart is how much they cost. Medicines in the US cost 2 to 6 times more than the rest of the world. 1 in 5 Americans - 35 million people - do not get their prescriptions filled because they don't have enough money. Big Pharma says high prices are necessary to invest in breakthrough research. But corporations don't actually do much of that, [and] have shifted money away from new-drug research to quick-profit minor variations on proven moneymakers. So who funds new-drug and breakthrough-drug research? Taxpayers. 84% of new-drug research is funded by the government. The public also subsidizes drug research through generous R&D tax credits. Using public research (plus charging high prices) gives corporations big profits. Drug companies' annual stock returns are twice the standard.

Note: A comprehensive infographic showing Big Pharma's preferential treatment by US regulators can be found at the link above. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the pharmaceutical industry.

Leaked internal emails appear to show employees at one of the world’s leading pharmaceutical companies calling for “celebration” over price hikes of cancer drugs. After purchasing five different cancer drugs from British firm GlaxoSmithKline, [Aspen Pharmacare] tried to sell the medicines ... for up to 40 times their previous price. When bargaining over drug prices in Spain, the pharmaceutical giant is said to have threatened to stop selling the cancer treatments unless the health minister agreed to price rises of up to 4,000 per cent. Now another leaked email appears to reveal that staff at Aspen discussed destroying their supplies of the drug in the row. The price increases were made possible by a loophole that allows drug companies to change the price of medicines if they are no longer branded with the same name. The loophole is designed to make drugs cheaper once their patents have expired – but if drug companies have no competition, they are free to rise prices as well. A ruling by the Italian competition watchdog found Aspen had taken an “aggressive” approach to negotiations in the country. The company said it would stop supplying Italy with the drugs in October 2013 if authorities did not agree to price rises of up to 2,100 per cent in three months.

Note: For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.

To combat an escalating opioid epidemic, the Drug Enforcement Administration trained its sights in 2011 on Mallinckrodt Pharmaceuticals, one of the nation’s largest manufacturers of the highly addictive generic painkiller oxycodone. It was the first time the DEA had targeted a manufacturer of opioids for alleged violations of laws designed to prevent diversion of legal narcotics to the black market. Ultimately, the DEA and federal prosecutors would contend that the company ignored its responsibility to report suspicious orders as 500 million of its pills ended up in Florida between 2008 and 2012. Investigators alleged in internal documents that the company’s lack of due diligence could have resulted in nearly 44,000 federal violations and exposed it to $2.3 billion in fines. But six years later ... the government has taken no legal action against Mallinckrodt. Instead, the company has reached a tentative settlement. Under the proposal, which remains confidential, Mallinckrodt would agree to pay a $35 million fine and admit no wrongdoing. “Mallinckrodt’s response was that ­‘everyone knew what was going on in Florida but they had no duty to report it,’” according to an internal summary of the case prepared by federal prosecutors. The Post reported in October that the DEA’s civil and administrative enforcement efforts against the mammoth wholesale distributors that deliver painkillers to pharmacies stalled in the face of a stepped-up lobbying campaign by the drug industry.

Note: The city of Everett, Washington is currently suing Purdue Pharma, maker of the opioid pain medication OxyContin, for the company's alleged role in the diversion of its pills to black market buyers. For other reliable information on pharmaceutical involvement in the huge increase in opioid deaths, see Dr. Mercola's excellent article. For more along these lines, see concise summaries of deeply revealing pharmaceutical corruption news articles from reliable major media sources.

As deaths from painkillers and heroin abuse spiked and street crimes increased, the mayor of Everett took major steps to tackle the opioid epidemic devastating this working-class city north of Seattle. Mayor Ray Stephanson stepped up patrols, hired social workers to ride with officers and pushed for more permanent housing for chronically homeless people. The city says it has spent millions combating OxyContin and heroin abuse. So Everett is suing Purdue Pharma, maker of the opioid pain medication OxyContin, in an unusual case that alleges the drugmaker knowingly allowed pills to be funneled into the black market and the city of about 108,000. “Purdue Pharmaceuticals was knowingly putting OxyContin into the black market in our community,” Stephanson told CBS Seattle affiliate KIRO-TV earlier this year. He said the opioid crisis caused by “Purdue’s drive for profit” has overwhelmed the city’s resources, stretching everyone from first responders to park crews who clean up discarded syringes. In 2007, Purdue Pharma and its executives paid more than $630 million in legal penalties to the federal government for willfully misrepresenting the drug’s addiction risks. The same year, it also settled with Washington and other states that claimed the company aggressively marketed OxyContin ... while downplaying the addiction risk. A Los Angeles Times report [published last summer] found Purdue had evidence that pointed to illegal trafficking of its pills but in many cases did nothing to notify authorities or stop the flow.

Note: For other reliable information on pharmaceutical involvement in the huge increase in opioid deaths, see Dr. Mercola's excellent article. For more along these lines, see concise summaries of deeply revealing pharmaceutical corruption news articles from reliable major media sources.

The latest poster child for cruel and inhuman drug pricing is Kaleo Pharma, maker of an emergency injector for a med called naloxone, which is used as an antidote to save the lives of people who overdose on painkillers. As America’s opioid crisis reaches epidemic levels, Kaleo has jacked up the list price for its Evzio auto-injector by 600%, soaring from $690 several years ago to $4,500, according to lawmakers. Nearly three dozen senators wrote to Kaleo’s chief executive, Spencer Williamson, last week to say they were “deeply concerned” about the price hike and to note that it “threatens to price out families and communities that depend on naloxone to save lives." But that’s not what caught my attention. Rather, I was struck by the company’s answers to me about lawmakers’ concerns. In response to emailed questions, Williamson said that although the list price for Evzio is more than $4,000, that’s “not a true net price to anyone … due to numerous discounts and rebates that are negotiated in the supply chain that make up our healthcare system.” In other words, even though the price tag for his company’s easy-to-use, lifesaving device is ridiculous and indefensible, there’s no need to worry because backroom deals by assorted players in the healthcare food chain make that price tag meaningless. And that, in a nutshell, illustrates the lunacy of the U.S. healthcare system.

Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and income inequality.

It was Tuesday morning. The new president was about to go into a meeting with chief executives from Johnson & Johnson, Merck and a handful of other major pharma companies. During his campaign, he often said that if he were elected, the federal government would start negotiating with the drug companies over the prices Medicare and Medicaid had to pay for drugs -- something it's now prevented from doing by statute. Pharma companies were "getting away with murder," he said on Jan. 10. A few weeks later, he claimed that the government would save $300 billion if it could negotiate prices. "We don't do it," he said. "Why? Because of the drug companies." "We have to get prices down," he says at the beginning of the meeting with cameras rolling. "We have no choice." Then the doors were closed. When they opened again, Trump had not only abandoned his promise to use the government's bargaining power to bring down drug prices, he was now totally against it! "I'll oppose anything that makes it harder for smaller, younger companies to take the risk of bringing their product to a vibrantly competitive market," he said. "That includes price-fixing by the biggest dog in the market, Medicare, which is what's happening." He accused an agency that has no power to negotiate prices of "price-fixing." And so it was that after one meeting with pharma CEOs, Trump was turned around on his one good idea and embraced instead yet another nonsensical one.

Note: For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.

Vaccines are ... under investigation for the possible side effects they can cause. In order to supply new information, an electron-microscopy investigation method was applied to the study of vaccines, aimed at verifying the presence of solid contaminants by means of an Environmental Scanning Electron Microscope equipped with an X-ray microprobe. The results of this new investigation show the presence of micro- and nanosized particulate matter composed of inorganic elements in vaccines' samples which is not declared among the components and whose ... presence is, for the time being, inexplicable. A considerable part of those particulate contaminants have already been verified in other matrices and reported in literature as non biodegradable and non biocompatible. The evidence collected is suggestive of some hypotheses correlated to diseases that are mentioned and briefly discussed. Recently, with the worldwide-adopted vaccines against Human Papillomavirus (HPV), the debate was reawaken[ed] due to some adverse effects reported by some young subjects. Specific studies communicated the existence of symptoms related to never-described-before syndromes developed after the vaccine was administered. For instance, Complex Regional Pain Syndrome (CRPS), Postural Orthostatic Tachycardia Syndrome (POTS), and Chronic Fatigue Syndrome (CFS) ... side-effects that can arise within a relatively short time can be local or systemic.

Note: For lots more, see this highly revealing article. For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.

As a social worker, Susannah Rose referred clients with cancer to patient advocacy groups she trusted to dispense unbiased advice - until she heard the groups might be taking money from pharmaceutical companies. So she set out to investigate. Two-thirds of patient advocacy organizations reported receiving industry funding, Rose, now a bioethicist, finds in a new study. Her research was published ... in JAMA Internal Medicine along with other studies showing a host of ways pharmaceutical manufacturers appear to pay for influence. Rose and her colleagues identified 7,865 patient advocacy organizations in the U.S., most involving cancer and rare or genetic disorders. They surveyed a random sample of the organization's leaders. More than 67 percent of 245 patient advocacy groups reported receiving industry funding in the past year. Of those, nearly 12 percent reported that more than half their funding came from industry. When the U.S. Centers for Disease Control and Prevention drafted guidelines for prescribing opioids for chronic pain in an effort to curtail a growing epidemic of abuse of the painkillers in 2015, nonprofit organizations stepped in to challenge the effort. The CDC postponed releasing the guidelines and solicited public comments for 30 days. Opioid manufacturers gave money to 45 of 158 patient advocacy and professional organizations that commented on the proposed guidelines. Organizations with funding from opioid manufacturers were significantly more likely to oppose them, researchers found.

Note: It's interesting to note that apparently no other major media picked up this Reuters article. Drug company executives have recently been caught bribing doctors to over-prescribe opioids, and ex-DEA official has publicly accused Congress of helping drug makers avoid responsibility for their role in the US opioid epidemic. For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.

Morphine is an opioid pain medication which can have severe adverse effects. These include drowsiness, dizziness, constipation, stomach pain, nausea, vomiting, headache, tired feeling, anxiety and mild itching. Other risks associated with morphine use include misuse, abuse and addiction. In addition, scientific research has shown that prescription opioids may actually worsen chronic pain. It appears that a holistic alternative to treating pain is much-needed in order to mitigate the dangers of conventional pharmaceutical pain treatment. Now, a groundbreaking study shows that acupuncture is one of these effective holistic alternatives. Considering the study results, it may perhaps be even more effective than morphine. The [new] research evaluated 300 emergency patients. 150 were administered up to 15 mg of morphine per day. The other 150 were given acupuncture treatment. The acupuncture group in the study experienced significant pain reduction, and the effect occurred faster and with fewer side effects when compared to the morphine group. In 1996, acupuncture became an accepted form of medical treatment endorsed by the World Health Organization (WHO). The WHO based their endorsement on data from numerous controlled clinical trials conducted over the two previous decades. Undoubtedly, acupuncture can play a powerful role in pain management. It is an effective drug-free alternative to reducing pain with very few side effects that has been proven over the ages.

Note: Why wasn't this important study reported in the major media? Could it be that big Pharma has bought out the media with their billions in advertising dollars such that they won't report on discoveries that eat into their profits? For more along these lines, see concise summaries of deeply revealing news articles on pharmaceutical corruption from reliable major media sources.

Pharmaceutical companies are "getting away with murder," President-elect Donald Trump said during his Wednesday press conference. After Trump mentioned drug prices and pharmaceutical companies' tax inversions, the nine biggest pharmaceutical companies by market cap on the S&P 500 shed roughly $24.6 billion in 20 minutes. The SPDR S&P Biotech exchange-traded fund, which tracks pharmaceutical stocks, fell nearly 4% in that time, while the iShares Nasdaq Biotechnology Index fell 3% in the same period. Granted, the loss in market cap for big pharma is small relative to companies' overall market cap - a 3% decrease from their combined $906.8 billion before Trump's speech. For the most part, pharmaceutical executives were relieved when Trump won the election. That's because Hillary Clinton, the one-time Democratic presidential nominee, heavily criticized drug companies on the campaign trail. Big pharmaceutical executives hoped that Trump would not come down as hard on their industry. Even now, it seems investors aren't all that worried about Trump's press conference criticisms: The SPDR S&P Biotech ETF is still up nearly 9% since election day. Merck's stock has managed to stay in the green despite losses during Trump's speech, thanks to news that the Food and Drug Administration had decided to speed up the review of a one of its lung-cancer treatments.

Note: Yet less than a month later, Trump completely changed his tune to support big Pharma, as shown in this Chicago Tribune article. For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.

Every year, more restaurants and food companies announce that they will sell only meat produced with minimal or no use of antibiotics. And every year, despite those pledges, more antibiotics are administered to the nation's swine, cattle and poultry. According to the latest figures, released this week by the U.S. Food and Drug Administration, antibiotic sales for use on farm animals increased by 1 percent in 2015, compared to the previous year. The increase was slightly greater – 2 percent — for antibiotics used as human medicine. The FDA and other public health agencies have been pushing farmers to rely less on these drugs. Heavy use of antibiotics both in human medicine and in agriculture has led to the emergence of drug-resistant bacteria, complicating the task of treating many infections. But the FDA finds a glimmer of good news in the latest figures, pointing out that the rate of increase has slowed. In the previous year, antibiotic use had increased by 4 percent, and a total of 22 percent from 2009 to 2014.

Note: For more along these lines, see concise summaries of deeply revealing news articles about food system corruption and health

A wide-ranging investigation into generic drug prices took its most significant turn yet on Thursday, as state attorneys general accused two industry leaders, Teva Pharmaceuticals and Mylan, and four smaller companies of engaging in brazen price-fixing schemes - and promised that more charges were coming. A civil complaint filed by 20 states accuses the companies of conspiring to artificially inflate prices on an antibiotic and a diabetes drug, with executives coordinating through informal industry gatherings and personal calls and text messages. Officials said the case was a small example of broader problems in the drug business. “We believe that this is just the tip of the iceberg,” George C. Jepsen, Connecticut’s attorney general, whose office started the inquiry that led to the charges, said. “I stress that our investigation is continuing, and it goes way beyond the two drugs in this lawsuit, and it involves many more companies than are in this lawsuit.” The complaint on Thursday describes a cozy industry culture defined by regular dinners and social outings, and argues that those events often cross the line to violate antitrust rules. Generic drug makers hoping to begin selling a new drug first seek out rivals, the suit says, in hopes of reaching an agreement on how to maintain market share and avoid competing on price. “These agreements had the effect of artificially maintaining high prices for a large number of generic drugs and creating an appearance of competition when in fact none existed,” the lawsuit says.

Note: A separate anti-trust investigation into Mylan was recently launched in New York over price-fixing on public school EpiPen contracts. For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.

FBI agents arrested former Insys Therapeutics CEO Michael Babich and five other former company executives on Thursday for allegedly bribing doctors to prescribe an extremely addictive opioid painkiller to patients who didn’t need it. The Department of Justice (DOJ) alleges that the executives took part in a “nationwide conspiracy” to give healthcare providers kickbacks in exchange for the improper prescribing of Subsys - an opioid medication containing the highly addictive substance fentanyl, which is considered even more dangerous than painkillers like Vicodin. Subsys is meant to provide pain relief to cancer patients who are going through particularly excruciating pain episodes. It’s reserved for these neediest of patients due to its potency and addictive qualities. But federal prosecutors allege that Babich and his co-conspirators doled out kickbacks to doctors who prescribed the drug even to non-cancer patients, and even set up a special “reimbursement unit” to sway insurance companies and pharmacy benefits managers to provide coverage for these non-authorized uses. The charges range from racketeering to conspiracy to mail and wire fraud. The FBI’s actions come in the wake of a newly invigorated federal effort to tackle the prescription painkiller epidemic, which has claimed the lives of more than 165,000 Americans since 1999.

Note: These charges come on the heels of an ex-DEA official's public accusation that Congress has been helping drug makers avoid responsibility for their role in the US opioid epidemic. How many deaths and ruined lives are being caused by greedy executives and the politicians in their pockets? For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.

A bipartisan coalition of lawmakers is rushing to finalize a new healthcare law that would overhaul the Food and Drug Administration (FDA). The bill, called the 21st Century Cures Act, is also a huge win for lobbyists: 1,455 lobbyists, working on behalf of 400 different healthcare companies, medical device makers and research institutions weighed in on the 900 pages of regulatory tweaks and research grants. Originally conceived as a bill to boost research ... pro-industry groups have used the bill as a vehicle to achieve their long standing legislative agenda. It effectively makes it easier for drug companies and medical device manufacturers to get FDA approval for their products without demonstrating that consumer safety has been taken into account. Consumer advocates are particularly concerned with several provisions that make it much easier for pharmaceutical companies to bypass stringent testing requirements to market and sell drugs for multiple uses. Currently, if a company wanted to sell a drug to treat more than one ailment, it must conduct randomized scientific trials showing the product does indeed work for each separate illness it's marketed for. The 21st Century Cures Act lowers that threshold. The bill also frees pharmaceutical companies to work with insurance companies to promote off-label uses for their drugs and creates a new category of ... medical devices which qualify for expedited regulatory approval. The lawmakers who introduced the measure are bankrolled by the healthcare industry.

Note: For more along these lines, see concise summaries of deeply revealing news articles about corruption in government and in the pharmaceutical industry.

Essential medicines could be provided for as little as $1-$2 US a month per person in developing countries, experts said on Monday as they called on governments to boost efforts to ensure everyone can access basic healthcare. Although global spending on medicines is about eight times this amount, one in five countries spends less than $1 per month per person, according to the first analysis of the cost of providing key drugs by The Lancet Commission on Essential Medicines. The commission, comprising 21 international experts, said lack of access to affordable, quality medicines was threatening progress towards universal health coverage. The list of essential medicines contains 201 drugs needed for a basic healthcare system. The commission estimated the cost of providing essential medicines to the populations of low- and middle-income countries to be between $77 billion and $152 billion a year. It said 41 countries were spending less than $1 per person per month on medicines while global spending on medicines in 2017 was predicted to be $1.2 trillion. The experts said "massive inequities and inefficiencies" in financing and governance were restricting access to drugs for many people. They said persistent problems with the quality and safety of medicines in many low- and middle-income countries must also be addressed with better regulation, [and] called for urgent reforms in the way essential drugs are developed and patented to improve affordability and access.

Note: For more along these lines, see concise summaries of deeply revealing news articles on income inequality and health.

A former top Drug Enforcement Administration (DEA) official has accused Congress of putting pharmaceutical company profits ahead of public health in the battle to combat the US’s prescription opioid epidemic. Joseph Rannazzisi, head of the DEA office responsible for preventing prescription medicine abuse until last year, said drug companies and their lobbyists have a “stranglehold” on Congress to protect a $9bn a year trade in opioid painkillers claiming the lives of nearly 19,000 people a year. Rannazzisi ... said the drug industry engineered recent legislation limiting the DEA’s powers to act against pharmacies endangering lives by dispensing disproportionately large numbers of opioids. He also accused lobbyists ... of whipping up opposition to new guidelines for doctors intended to reduce the prescribing of the painkillers. Charges that Congress is too beholden to pharmaceutical companies have been levelled for years. But ... the influence on opioid policies is particularly disturbing because so many lives are being lost. Industry groups have spent hundreds of millions of dollars in lobbying to stave off measures to reduce prescriptions and therefore sales of opioid painkillers. Among the most influential drug industry groups is the Pain Care Forum, co-founded by a top executive of Purdue Pharma – the manufacturer of the opioid which unleashed the addiction epidemic, OxyContin. It spent $740m lobbying Congress and state legislatures over the past decade.

Note: See also a Washington Post article for more. For more, see concise summaries of deeply revealing news articles on government corruption and Big Pharma profiteering.

Sugar pills worked as well at preventing kids' migraines as two commonly used headache medicines, but had fewer side effects, in a study that may lead doctors to rethink how they treat a common ailment in children and teens. It's the first rigorous head-to-head test in kids of two generic prescription drugs also used for adults' migraines: topiramate, an anti-seizure medicine, and amitriptyline, an anti-depressant. The idea was to see if either drug could reduce by half the number of days kids had migraines over a month's time. Both drugs worked that well - but so did placebo sugar pills. The results "really challenge what is typical practice today by headache specialists," said study author Scott Powers, a psychologist at Cincinnati Children's Hospital. "The fact that it shows that two of the most commonly used medications are no more effective than a placebo and have adverse effects makes a very clear statement," said Dr. Leon Epstein, neurology chief at Ann & Robert Lurie H. Children's Hospital of Chicago. The only government-approved migraine medication for kids is topiramate. Side effects from the drugs [included] fatigue, dry mouth and forgetfulness. Kids on topiramate also had tingling sensations in their hands, arms, legs or feet. There was one suicide attempt in the topiramate group, another known side-effect of that drug. The side effects were not unexpected, but given the risks, the results suggest the drugs shouldn't be "first-line prevention treatments" for kids' migraines, Powers said.

Note: This study was published in the New England Journal of Medicine. For more, see this mercola.com article. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources.

Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.